Generex Biotechnology Subsidiary Olaregen Therapeutics’ Wound Conforming Matrix, Excellagen, Awarded Strategic Acquisition Centers (SAC) Biologic Blanket Purchase Agreement (BPA) Contract

• The BPA contract facilitates the sales and distribution of Excellagen across the VA system’s 165 hospitals
  
• Excellagen wound conforming matrix is used to manage wounds including Diabetic Foot Ulcers, that affect a staggering 21% of our veterans

MIRAMAR, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) proudly announced that the company’s subsidiary Olaregen Therapeutics’ wound conforming matrix, Excellagen, has been awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC) through the efforts of AvMedical, Olaregen’s Small Disabled Veteran Owned Small Distributor (SDVOSD) partner.  The VA’s National Contract and National BPA programs are used by VA medical centers, related facilities, specific State Veterans Homes, and other Federal facilities to procure select products based on clinical evidence, patient outcomes, and economic cost to the VA hospitals.  The SAC awarded Excellagen a position on their biologics BPA through a rigorous evaluation of price, level of clinical evidence, and clinical efficacy that demonstrated the benefits of Excellagen for the management of hard to heal wounds. This award will expedite the purchasing of Excellagen at over 165 VA medical centers across the U.S. and Puerto Rico that treat veterans who suffer from diabetic foot ulcers, venous leg ulcers, and other difficult to manage wounds that disproportionately impact the veteran population.

Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex said, “This is an exciting day for the commercialization of Excellagen in the VA Healthcare System. We started the BPA process with our distribution partner AvMedical back in August 2019, and we were always confident that Excellagen would offer positive clinical outcomes for veterans who are dealing with hard to heal wounds.  Today, Excellagen is bringing great outcomes to several large VA hospitals, and with this new contract, we expect to expedite the acquisition process for Excellagen across the system thanks to the upfront work that has already been completed and approved by the SAC. The streamlined BPA ordering procedures reduce procurement lead time and administrative costs for our VA customers, and we expect this to have a significant impact of future sales.”